Login to Your Account

FDA unduly dour regarding value of off-label communication

By Mark McCarty
Regulatory Editor

Monday, April 24, 2017

The docket for the FDA's most recent efforts to address the off-label question drew dozens of comments, many of which were at least modestly supportive of the changes in the agency's stance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription